The Efficacy of Pre-procedural Mouth Rinses on COVID-19 Saliva Viral Load

Sponsor

King Abdulaziz University (Other)

Overall Status

Completed

CT.gov ID

NCT04721457

Collaborator

(none)

Enrollment

Location

Arms

11.2

Actual Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Preoperative antiseptic mouth rinses have been widely used as a standard protocol before routine dental treatment reduces oral microorganism counts. During dental procedures, aerosolized microorganisms contaminate the dental environment and nearby surfaces and remain suspended for 4 hours. Thus, the reduction in the number of aerosolized microorganisms by pre-procedural rinsing may reduce cross-contamination between dentists, office personnel, and patients. Recent reviews have advocated the use of preoperative rinsing to control and reduce the risk of SARS-CoV-2 transmission. However, no clinical studies have been done yet to support the effectiveness of any pre-procedural oral rinses against SARS-CoV-2. The proposed study will mitigate the spread of COVID-19 disease in dental healthcare facilities and ensure the patients' good health and healthcare workers. The purpose of this clinical trial is to compare the efficacy of four commercially available mouth rinses povidone-iodine (PVP-I), hydrogen peroxide (H2O2), cetylpyridinium chloride (CPC), sodium hypochlorite (NaOCl) on the salivary SARS-CoV-2 viral load at four-time points (baseline and 5-, 30-, and 60-min post rinsing) relative to two control groups (distilled water and no-rinse) in a cohort of positive COVID-19 patients.

Condition or Disease	Intervention/Treatment	Phase
SARS-CoV-2 COVID-19 Mouthwashes Viral Load Polymerase Chain Reaction Coronavirus Covid19 Saliva	Drug: Distilled Water Drug: 1% Povidone Iodine (PVP-I) Drug: 1.5% Hydrogen Peroxide (H2O2) Drug: 0.075% Cetylpyridinium Chloride (CPC) Drug: 0.1% Sodium Hypochlorite Other: No rinse group	Phase 4

Detailed Description

Saliva specimens will be collected from COVID-19-positive patients presenting to TETAMMAN clinics from January to March 2021. The total number of participants in this study will be 90 participants, with 15 per group (6 groups), and 4 saliva specimens from each patient in each group. A total of four mouth rinses and two control groups (distilled water and no-rinse). The studied mouth rinses were: 1% povidone-iodine (PVP-I) (Betadine Mouthwash/Gargle; Avrio Health LP, Stamford, CT, USA), 1.5% hydrogen peroxide (H2O2) (Peroxyl; Colgate-Palmolive, Guildford, UK), 0.075% cetylpyridinium chloride (CPC) (Colgate Total; Colgate-Palmolive, Guildford, UK), 80 ppm sodium hypochlorite (NaOCl) (Clinisept Dental Mouthwash; Clinical Health Technologies, Hinckley, Leicestershire, UK). Confirmed positive cases of COVID-19 will be recruited randomly at each TETAMMAN clinic based on inclusion and exclusion criteria to satisfy the total of 90 patients. Each participant will be introduced briefly to the study aims and then asked to sign a consent form. Demographic data and medical history will then be collected for each participant. The participants will be blinded to all mouth rinses, which will be labeled with identification codes, and presented in similar packages. Unstimulated saliva will be collected using the passive drool technique. Four saliva samples for each patient will be collected. The first saliva sample will be considered as a baseline sample that represents the baseline viral load. Then patients will be instructed to gargle the assigned mouth rinse gently, for 15 seconds. After that, the participants will spit the mouthwashes into a disposable plastic cup. After that, different salivary samples will be collected at 5 minutes, 30 minutes, and then 60 minutes. Thus, a total of four saliva samples will be gathered from each patient. The viral load will be measured by quantitative reverse transcription PCR.

Study Design

Study Type:

Interventional

Actual Enrollment :

90 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

This randomizeda, single-center, randomized, double-blind, six-parallel-group, placebo-controlled trial compares the efficacy of four commercially available mouth rinses povidone-iodine (PVP-I), hydrogen peroxide (H2O2), cetylpyridinium chloride (CPC), sodium hypochlorite (NaOCl) on the salivary SARS-CoV-2 viral load at four-time points (baseline and 5-, 30-, and 60-min post rinsing) relative to two control groups (distilled water and no-rinse) in a cohort of positive COVID-19 patients.This randomizeda, single-center, randomized, double-blind, six-parallel-group, placebo-controlled trial compares the efficacy of four commercially available mouth rinses povidone-iodine (PVP-I), hydrogen peroxide (H2O2), cetylpyridinium chloride (CPC), sodium hypochlorite (NaOCl) on the salivary SARS-CoV-2 viral load at four-time points (baseline and 5-, 30-, and 60-min post rinsing) relative to two control groups (distilled water and no-rinse) in a cohort of positive COVID-19 patients.

Masking:

Double (Participant, Investigator)

Masking Description:

Allocated mouth rinses will be concealed in opaque sealed envelopes. Each envelope contains a 15 ml sterile amber test tube filled with the assigned mouth rinse, a 120 ml sterile empty specimen container for expectoration of the mouth rinse, and four identical empty 50 ml sterile test tubes for collecting saliva samples, each labeled with the allocated number and time point (T0, T1, T2, or T3), and a biohazard bag.

Primary Purpose:

Prevention

Official Title:

Mouth Rinses Efficacy on Salivary SARS-CoV-2 Viral Load: A Randomized Clinical Trial

Actual Study Start Date :

Jan 3, 2021

Actual Primary Completion Date :

Mar 28, 2021

Actual Study Completion Date :

Dec 10, 2021

Arms and Interventions

Arm	Intervention/Treatment
Placebo Comparator: Distilled Water Vigorously rinse with 15 ml of the distilled water for 30 s (Water for Injections BP; Pharmaceutical Solutions Industry, Jeddah, SA)	Drug: Distilled Water Control group Other Names: water (Water for Injections BP; Pharmaceutical Solutions Industry, Jeddah, SA)
Active Comparator: Povidone Iodine (PVP-I) Vigorously rinse with 15 ml of the 1% povidone-iodine (PVP-I) (Betadine Mouthwash/Gargle; Avrio Health LP, Stamford, CT, USA) for 30 s	Drug: 1% Povidone Iodine (PVP-I) Over-the-counter antiseptic mouth rinse Other Names: Betadine Mouthwash/Gargle; Avrio Health LP, Stamford, CT, USA
Active Comparator: Hydrogen Peroxide (H2O2) Vigorously rinse with 15 ml of the 1.5% hydrogen peroxide (H2O2) (Peroxyl; Colgate-Palmolive, Guildford, UK) for 30 s	Drug: 1.5% Hydrogen Peroxide (H2O2) Over-the-counter antiseptic mouth rinse Other Names: Peroxyl; Colgate-Palmolive, Guildford, UK
Active Comparator: Cetylpyridinium Chloride (CPC) Vigorously rinse with 15 ml of the 0.075% cetylpyridinium chloride (CPC) (Colgate Total; Colgate-Palmolive, Guildford, UK) for 30 s	Drug: 0.075% Cetylpyridinium Chloride (CPC) Over-the-counter antiseptic mouth rinse Other Names: Colgate Total; Colgate-Palmolive, Guildford, UK
Active Comparator: Sodium Hypochlorite Vigorously rinse with 15 ml of the 80 ppm sodium hypochlorite (NaOCl) (Clinisept Dental Mouthwash; Clinical Health Technologies, Hinckley, Leicestershire, UK) for 30 s	Drug: 0.1% Sodium Hypochlorite Over-the-counter antiseptic mouth rinse Other Names: Clinisept Dental Mouthwash; Clinical Health Technologies, Hinckley, Leicestershire, UK
Placebo Comparator: No rinse group There is no mouth rinse in this group. Patients will collect the saliva at all 4-time points without gargling with the mouth rinse.	Other: No rinse group second control group

Outcome Measures

Primary Outcome Measures

Change in the salivary viral load within each mouth rinse groups and controls [Baseline (T0) vs 5 minutes (T1), baseline (T0) vs 30 minutes (T2), and baseline (T0) vs 60 minutes T3)]
change in the salivary viral load overtime within each group will be measured by quantitative reverse transcription PCR (RT-qPCR) and expressed as copies/ml
Compare salivary viral load between mouth rinse groups and controls at baseline [Compare Baseline (T0)]
Difference in Salivary viral load baseline value between the groups
Compare salivary viral load between mouth rinse groups and controls at 5 minutes post rinsing [5 minutes post rinsing (T1)]
Difference in Salivary viral load baseline value between the groups
Compare salivary viral load between mouth rinse groups and controls at 30 minutes post rinsing [30 minutes post rinsing (T2)]
Difference in Salivary viral load baseline value between the groups
Compare salivary viral load between mouth rinse groups and controls at 60 minutes post rinsing [60 minutes post rinsing (T3)]
Difference in Salivary viral load baseline value between the groups

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Adults age 18 years or older presented to TETAMMAN clinics, Jeddah, Saudi Arabia.
COVID-19-positive patients confirmed by RT-PCR and within two days of oral or nasopharyngeal swabs
Asymptomatic or within seven days of the onset of symptoms.
Has the ability to rinse and expectorate.

Exclusion Criteria:

Participants who established antiviral, corticosteroid, antimicrobial, or immunosuppressive medications.
Known allergy to one of the constituents of the mouth rinse
Thyroid disease or on current radioactive iodine treatment
Pregnant or breastfeeding women
Lithium therapy
History of radiotherapy or chemotherapy
Use of mouthwash before presented to TETAMMAN clinics